Expanded Access to VAL-083

Conditions

Cancer

Brief summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Carlos Kamiya-Matsuoka, Shaio-Pei Weathers, Rebecca Harrison, Nazanin Majd, Ashley Aaroe et al. (11 authors)

Neuro-Oncology2024-11-01

10.1093/neuonc/noae165.0439

CTNI-71. RELA FUSION-POSITIVE EPENDYMOMA, DIFFUSE MIDLINE GLIOMA AND GRADE 4 IDH MUTANT ASTROCYTOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: CASE REPORTS

Carlos Kamiya-Matsuoka, Shaio-Pei Weathers, Stephanie Knight, Teresa Hanna, John Langlands et al. (7 authors)

Neuro-Oncology2024-11-01

10.1093/neuonc/noae165.0438

Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports

Carlos Kamiya-Matsuoka, Stephanie Knight, Teresa Hanna, Timothy A. Gregory, John Langlands et al. (7 authors)

Cancer Research2023-04-141 citations

10.1158/1538-7445.am2023-lb126

Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program

Carlos Kamiya-Matsuoka, Shiao‐Pei Weathers, Rebecca A. Harrison, Nazanin Majd, Ashley Aaroe et al. (11 authors)

Cancer Research2023-04-14

10.1158/1538-7445.am2023-lb127

DDDR-34. RECURRENT RELA FUSION-POSITIVE EPENDYMOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: A CASE REPORT

Carlos Kamiya-Matsuoka, Stephanie Knight, John Langlands, Dennis Brown, Vinay K. Puduvalli

Neuro-Oncology2022-11-01

10.1093/neuonc/noac209.399

DDDR-36. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM

Carlos Kamiya-Matsuoka, Nazanin Majd, R. C. Harrison, Stephanie Knight, John Langlands et al. (7 authors)

Neuro-Oncology2022-11-01

10.1093/neuonc/noac209.401

Interventions

DRUGVAL-083

VAL-083 will be administered intravenously

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient has relapsed/refractory disease and exhausted all standard treatments.

Exclusion criteria

* Patient is eligible for a VAL-083 clinical trial. * Patient has previously received VAL-083 for the same disease.

Outcome results

None listed